Table 2.
Demographics and baseline characteristics
| Placebo | Exenatide | |
|---|---|---|
| N | 10 | 10 |
| Age (y) | 42.5 (25.3–49.5) | 34 (33–46.8) |
| Gender, female (%) | 70 | 60 |
| Ethnicity, Caucasian/Hispanic (%) | 90/10 | 90/10 |
| Body weight (kg) | 103.4 (87.6–111.9) | 98.1 (89.4–109.7) |
| BMI (kg/m2) | 34.2 (31.7–38.5) | 33.5 (32.9–36.7) |
| Waist circumference (cm) | 108.5 (105–118) | 107.7 (100–121) |
| Solid GE: proportion emptied at 1 h | 43.5 (36–51.9) | 41.8 (35.1–45.1) |
| Solid GE T½ min | 77.6 (56.4–94.2) | 79.4 (70.1–98.1) |
| Volume to fullness, mL (mL) | 630 (412–975) | 690 (413–975) |
| Maximum tolerated volume (mL) | 1185 (941–1422) | 1304 (1035–1807) |
| Aggregate satiation symptoms (VAS, mm) | 160 (118–247) | 199.5 (121–235) |
| Nausea (VAS, mm) | 20 (4.8–58.8) | 28.5 (10.3–58) |
| Fullness (VAS, mm) | 66.5 (47–79) | 73 (60.5–82.8) |
| Bloating (VAS, mm) | 64 (26.5–78.3) | 62 (40.3–70) |
| Pain (VAS, mm) | 28 (7.8–70) | 22 (6–30.3) |
Data are median (IQR). Data on gastric emptying (GE) are from same participants in prior studies; symptoms appraised using 100-mm visual analog scales (VAS).